Prajeeth, Chittappen K <br/><br/>
The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens.  [electronic resource] 

 -  European journal of immunology  May 2010 
 - 1272-83 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1521-4141 
<br/><br/><label>Standard No.: </label>10.1002/eji.200939790  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--pharmacology<br/>Amino Acid Sequence<br/>Animals<br/>Antigen Presentation--drug effects<br/>Antigens--administration & dosage<br/>Bone Marrow Cells--immunology<br/>CD4-Positive T-Lymphocytes--immunology<br/>Dendritic Cells--classification<br/>Drug Evaluation, Preclinical<br/>H-2 Antigens--immunology<br/>Lipopeptides--administration & dosage<br/>Mice<br/>Mice, Inbred C57BL<br/>Molecular Sequence Data<br/>Oligopeptides--chemical synthesis<br/>Ovalbumin--administration & dosage<br/>Peptide Fragments--administration & dosage<br/>Polyethylene Glycols--administration & dosage<br/>Spleen--cytology<br/>T-Lymphocytes, Cytotoxic--immunology<br/>Toll-Like Receptor 2--agonists